labetalol hydrochloride 200 mg
INDICATIONS AND USAGE Labetalol hydrochloride tablets, USP are indicated in the management of hypertension. Labetalol hydrochloride tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics.
innogenix, inc.
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
HOW SUPPLIED
LABETALOL HYDROCHLORIDE Tablets, USP, for oral administration, are available as 100 mg : round, beige, film-coated tablets, plain on one side, scored and debossed with “I/126” on the other side and supplied as: NDC 71247-126-01 bottles of 100 NDC 71247-126-05 bottles of 500 200 mg : round, white, film-coated tablets, plain on one side, scored and debossed with “I/127” on the other side and supplied as: NDC 71247-127-01 bottles of 100 NDC 71247-127-05 bottles of 500 300 mg : round, blue, film-coated tablets, plain on one side and debossed with “I/130” on the other side and supplied as: NDC 71247-130-01 bottles of 100 NDC 71247-130-05 bottles of 500
LABETALOL HYDROCHLORIDE Tablets, USP should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP with a child-resistant closure as required. To report SUSPECTED ADVERSE REACTIONS, contact Innogenix, LLC. at 1-844-466-6469 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Distributed by: Innogenix, LLC. Amityville, NY 11701 Rev. 09/2020
More pills like ROUND I 127